Amgen quarterly profit slips, obesity data on track for late 2024
Adds analyst comment paragraph 4, company comment paragraph 10; updates share price
By Deena Beasley
Aug 6 (Reuters) -Amgen AMGN.O on Tuesday said its second-quarter profit slipped 1% as higher expenses, including costs related to development of its experimental obesity drug MariTide, offset a 20% increase in revenue driven by the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
Amgen reported adjusted earnings of $4.97 per share, which was 3 cents shy of the average analyst estimate, according to LSEG data.
Quarterly revenue of $8.39 billion was slightly ahead of the $8.37 billion forecast by analysts.
"The quarter overall looks fairly uneventful," Mizuho analyst Salim Syed said in a research note, adding that the earnings miss was driven by slightly weaker margins and a slightly higher share count.
Amgen shares, which closed up 1% at $328.95, were down 2% after hours.
Second-quarter sales of cholesterol drug Repatha rose 25% to $532 million, while sales of older rheumatoid arthritis drug Enbrel fell 15% to $902 million.
Sales of Tepezza, Horizon's thyroid eye disease drug, rose 7% from a year earlier to $479 million, while gout drug Krystexxa saw sales rise 20% to $294 million.
Excluding Horizon's drugs, Amgen said product sales grew 5%.
Investors are focused on progress with the weight-loss drug MariTide. The company said it expects to have initial data from a mid-stage trial of the medicine late this year.
It also plans to begin human testing of a different obesity drug candidate before the end of the year.
For MariTide, "we are laser focused on preparing to quickly launch a broad Phase 3 program in obesity, obesity-related conditions and diabetes," Amgen Chief Financial Officer Peter Griffith said in an interview.
Some analysts have forecast the market for new drugs for weight loss reaching $130 billion a year by the early 2030s.
Griffith said Amgen raised its capital spending target for full-year 2024 to $1.3 billion from $1.1 billion due in part to investment in MariTide and its manufacturing.
Amgen also raised the lower end of its 2024 revenue outlook to a range of $32.8 billion to $33.8 billion from a previous low end forecast of $32.5 billion.
Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19.10 to $20.10 per share, compared with its previous view of $19.00 to $20.20.
Analysts have forecast 2024 earnings per share of $19.51 on revenue of $33.1 billion.
Reporting By Deena Beasley in Los Angeles
Editing by Bill Berkrot
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
